News | May 23, 2026
Gujarat Themis Biosyn acquires MicroBiopharm Japan for Rs. 1,300 Cr
Transition to a fermentation-based globally integrated CDMO platform
Transition to a fermentation-based globally integrated CDMO platform
Diagnostic-guided healthcare platform strengthens leadership team to accelerate AI-driven diagnostics and consumer healthcare expansion
Q4FY26 revenue rises 13.6% to Rs. 14,560 crore; quarterly net profit jumps 26.2% to Rs. 2,714 crore driven by India business and Innovative Medicines growth
Company’s FY26 EBITDA rses 20% to Rs. 8,475 crore; Net profit grows 15% amid strong operational performance
Combined footprint expands to 420 hearing care centres across India
Growth driven by strong performance across Sugar Free, RiteBite Max Protein, Everyuth, Glucon-D and Nutralite portfolios
The platform combines internally developed technologies, strategic partnerships, and external AI capabilities
The company reported a 108% rise in profit after tax, driven by strong growth in regulated markets, branded generics, and U.S. expansion initiatives
Global specialty pipeline accelerates growth
The company’s shares of confidence were underlined by an upgraded 2026 outlook, with Merck now expecting annual net sales of up to €21.4 billion and EBITDA pre of as much as €6.1 billion
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
